Development asset linked to RIGEL PHARMACEUTICALS in public FDA and regional records.
pharma · Rheumatoid Arthritis · Warm Antibody Autoimmune Hemolytic Anemia · RIGL
RIGEL PHARMACEUTICALS
RIGEL PHARMACEUTICALS INC
RIGEL PHARMACEUTICALS drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
1180 Veterans Blvd, South San Francisco, CA 94080, US HQ
1996 Founded
286 Employees
Public company Type
RIGL · NYSE Ticker
Company details
- Status
- Public
- HQ
- 1180 Veterans Blvd, South San Francisco, CA 94080, US
- Founded
- 1996
- Employees
- 286
- Programs
- 1
- Drugs
- 9
- Patents
- 14
RIGEL PHARMACEUTICALS pipeline
Portfolio lens on 9 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
RIGEL PHARMACEUTICALS drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
fostamatinib
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in RIGEL PHARMACEUTICALS's portfolio. Molecular target: Tyrosine-protein kinase SYK.
- Target
- Tyrosine-protein kinase SYK
- Mechanism
- Tyrosine-protein kinase SYK inhibitor
-
US regulatory status: approved. Molecular target: Tyrosine-protein kinase SYK.
- Target
- Tyrosine-protein kinase SYK
- Mechanism
- Tyrosine-protein kinase SYK inhibitor
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
imiquimod
Dermatologicals (D06)US regulatory status: approved. Molecular target: Toll-like receptor 7.
- Target
- Toll-like receptor 7
- Mechanism
- Toll-like receptor 7 agonist
-
US regulatory status: approved. Molecular target: Isocitrate dehydrogenase [NADP] cytoplasmic.
- Target
- Isocitrate dehydrogenase [NADP] cytoplasmic
- Mechanism
- Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
pralsetinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET.
- Target
- Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET
- Mechanism
- Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor
-
ruxolitinib
Dermatologicals (D11)US regulatory status: approved. Mechanism: Tyrosine-protein kinase JAK2 inhibitor.
- Mechanism
- Tyrosine-protein kinase JAK2 inhibitor